What is the mechanism of progression with trastuzumab treatment--escape or resistance?

Content Provider	Semantic Scholar
Author	Şendur, Mehmet Ali Nahit Aksoy, Sercan Özdemir, Nuriye Yildirim Zengin, Nurullah Altundag, Kadri
Copyright Year	2012
Abstract	Human epidermal growth factor receptor (HER) 2 overexpression, observed in 20-25 percent of invasive breast cancers, is well known to be associated with a more aggressive phenotype and poor prognosis, with resistance to certain chemotherapeutic agents. The majority of patients with metastatic breast cancer who initially respond to trastuzumab, demonstrate disease progression within 1 year of treatment initiation. Furthermore, lack of response in some patients and relapse during the course of therapy, continue to challenge researchers and clinicians. A better understanding of the fundamental mechanisms of trastuzumab action is required so that new therapies directed at HER2 can be developed. We present here findings for mechanisms, both of Trastuzumab action and clinical resistance or escape.
File Format	PDF HTM / HTML
Alternate Webpage(s)	http://ocean.kisti.re.kr/downfile/volume/apocp/POCPA9/2012/v13n11/POCPA9_2012_v13n11_5915.pdf
PubMed reference number	23317282v1
Volume Number	13
Issue Number	11
Journal	Asian Pacific journal of cancer prevention : APJCP
Language	English
Access Restriction	Open
Subject Keyword	Carcinoma breast stage IV Epidermal Growth Factor Receptor Growth Factor Receptors Inflammatory Breast Carcinoma Mammary Neoplasms Paget's Disease, Mammary Patients Therapeutic procedure Transcription Initiation trastuzumab
Content Type	Text
Resource Type	Article